Acer Therapeutics is developing therapies for serious rare diseases with significant unmet need. We are working to obtain FDA approval for Edsivo™(celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the US. We are also advancing ACER-001 for the treatment of Maple Syrup Urine Disease (MSUD) and Urea Cycle Disorders (UCDs).